Generic version of remdesivir at Rs 4,000 per vial launched by CIPLA

Cipla, Pharma Giant on Wednesday has announced that it has launched its generic version of antiviral drug remdesivir at Rs 4,000 per vial, which is among the lowest globally, and is looking to supply over 80,000 vials within the first month. Cipremi is priced at Rs 4,000 per 100 mg vial, according to the statement by Cipla.

Nikhil Chopra said in an e-mailed statement that, “We are proud to commercially launch Cipremi today (on Wednesday); amongst the lowest priced globally, and aim to supply over 80,000 vials within the first month itself,” Cipla Executive Vice-President and CEO (India Business).To further ensure equitable distribution, the drug will be available through government and hospital channels only, he added. “Cipla will also be donating some amount of the drug as part of its efforts to support the community in this time of need.
The Drug Controller General of India has approved Cipremi for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need.

Remdesivir has been approved by United States Food and Drug Administration (USFDA) for Emergency Use Authorisation (EUA) treatment for adult and pediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection.
Earlier in May, pharma firms Hetero, Cipla and Jubilant Life Sciences entered into non-exclusive licensing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of remdesivir.

  • Related Posts

    • Pharma
    • July 24, 2025
    • 156 views
    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

    • Pharma
    • July 22, 2025
    • 241 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra